TTK Healthcare Q4 Results FY26: Revenue, PAT, Net Profit and Key Highlights

TTK Healthcare Q4 results for the quarter ended March 2026 show revenue of Rs 218 crore (+15% year on year) and net profit of Rs 22 crore (+38% year on year). Reported on a Standalone basis, these numbers reflect TTK Healthcare’s core Healthcare / Pharma performance through Q4 FY25-26. This article covers the full financial breakdown, margin analysis, and FY27 outlook to help investors make informed decisions about TTK Healthcare.

Click Here – Get Free Investment Predictions

TTK Healthcare Q4 FY26 Financial Highlights

The table below summarises key financial metrics comparing Q4 FY26 with Q4 FY25 on a Standalone basis.

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue from Operations	218	190	+15%
Gross Profit	9	10	-10%
Gross Margin	4.1%	5.3%
Net Profit (PAT)	22	16	+38%
PAT Margin	10.1%	8.4%

Detailed Analysis of TTK Healthcare Q4 Results

Check the Univest Screener for live TTK Healthcare data

Revenue grew to Rs 218 crore in Q4 FY26 from Rs 190 crore in the year-ago quarter, a +15% change year on year. The Healthcare / Pharma segment drove the top line through this period, with demand conditions and pricing realisations shaping the quarterly revenue outcome. Investors tracking TTK Healthcare Q4 results are watching whether this revenue run rate sustains into FY27.

Gross profit stood at Rs 9 crore at a margin of 4.1%, compared to Rs 10 crore and 5.3% in Q4 FY25. The gross margin movement reflects input cost dynamics and product mix across TTK Healthcare’s operations. Kunal Singla, Associate Director at Univest, notes that margin outcomes in the Healthcare / Pharma sector are sensitive to commodity cost cycles that played out through Q4 FY26.

Net profit rose to Rs 22 crore from Rs 16 crore in Q4 FY25. At a PAT margin of 10.1%, the earnings quality reflects how efficiently TTK Healthcare is converting revenue to bottom-line income. Kunal Singla highlights that the TTK Healthcare Q4 results set a key profitability baseline for assessing FY27 earnings potential.

Key Business Factors in Q4 FY26

Revenue Drivers and Volume Trends

The +15% revenue change to Rs 218 crore in Q4 FY26 reflects TTK Healthcare’s demand conditions and order execution in the Healthcare / Pharma space. Volume performance, customer mix, and realisation per unit each contributed to the quarterly top-line figure. Whether this revenue level is sustainable into FY27 remains a key question for investors tracking the stock.

Gross Margin and Cost Management

A gross margin of 4.1% in Q4 FY26 reflects TTK Healthcare’s cost management posture within the Healthcare / Pharma segment. Input cost trends, freight expenses, and production efficiencies shaped this outcome. Sustaining or improving gross margins into FY27 will depend on TTK Healthcare’s ability to control costs as revenue scales through the year.

Profitability and Earnings Quality

Net profit of Rs 22 crore at a 10.1% PAT margin reflects TTK Healthcare’s earnings conversion in Q4 FY26. Finance costs, tax provisions, and non-operating items all influence the final PAT figure. The repeatability of these earnings will be central to how the company is valued heading into FY27.

Dividend Details

TTK Healthcare has not announced any dividend for Q4 FY26 as per information available on May 30, 2026. Investors should track official BSE/NSE filings for any board-level decisions on dividends or capital return for the full financial year FY26.

FY27 Outlook

TTK Healthcare enters FY27 with a revenue base of Rs 218 crore and net profit of Rs 22 crore from the TTK Healthcare Q4 results. The Healthcare / Pharma sector’s FY27 trajectory depends on domestic demand, input cost stability, and any regulatory changes that affect the broader operating environment.

Kunal Singla suggests that investors tracking TTK Healthcare should monitor quarterly management guidance, order book updates, and margin improvement milestones closely through H1 FY27. The transition from TTK Healthcare Q4 results into a full-year FY27 delivery is a critical inflection point for long-term shareholders in the stock.

TTK Healthcare Stock Performance

Download the Univest Android App or Univest iOS App to track TTK Healthcare share price and get daily research updates.

TTK Healthcare shares are trading at Rs 922.6 as of May 30, 2026. The stock’s reaction to TTK Healthcare Q4 results reflects how the market is assessing the company’s performance relative to Healthcare / Pharma sector expectations. Live price data, technical analysis, and research coverage for TTK Healthcare are available on the Univest platform.

Key Risks for TTK Healthcare

Healthcare / Pharma Sector Headwinds

The Healthcare / Pharma industry faces risks from commodity price swings, regulatory shifts, and competitive pressure. Any deterioration in sector fundamentals could weigh on TTK Healthcare’s revenue and margin outlook beyond Q4 FY26 levels.

Macroeconomic and External Risks

Global growth concerns, FII outflows, and domestic inflation pressures pose risks to TTK Healthcare’s valuation multiples independent of operational performance. A weak demand environment or rising interest rates could compress near-term earnings.

Execution and Working Capital Risk

Sustaining Q4 FY26 revenue and profitability levels into FY27 requires consistent execution from TTK Healthcare’s management. Receivable elongation, working capital build-up, or unexpected capex commitments could pressure future quarterly cash flows and earnings quality.

Conclusion

TTK Healthcare Q4 results for Q4 FY26 show revenue of Rs 218 crore and net profit of Rs 22 crore, establishing a clear picture of the company’s financial position in the Healthcare / Pharma space. The +15% revenue change and +38% PAT movement provide a meaningful baseline for FY27 projections. Kunal Singla recommends that investors review these numbers alongside sector trends and management commentary before making any investment decisions related to TTK Healthcare.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Frequently Asked Questions on TTK Healthcare Q4 FY26 Results

When were the TTK Healthcare Q4 results announced?

Ans. The Q4 FY26 results for TTK Healthcare were declared on May 30, 2026, covering the quarter ended March 2026.

What was the revenue in TTK Healthcare Q4 results?

Ans. TTK Healthcare reported revenue of Rs 218 crore in Q4 FY26, compared to Rs 190 crore in Q4 FY25, a change of +15% year on year.

What was the net profit in TTK Healthcare Q4 results?

Ans. TTK Healthcare reported a net profit (PAT) of Rs 22 crore in Q4 FY26, compared to Rs 16 crore in Q4 FY25, a +38% change year on year.

What is the FY27 outlook after TTK Healthcare Q4 results?

Ans. TTK Healthcare enters FY27 with revenue of Rs 218 crore and PAT of Rs 22 crore as a baseline. The FY27 outlook depends on Healthcare / Pharma demand, cost management, and execution quality.

Did TTK Healthcare declare a dividend after TTK Healthcare Q4 results?

Ans. No dividend was declared for Q4 FY26 as per information available on May 30, 2026. Investors should check official exchange filings for any board announcements on capital returns.

How did TTK Healthcare shares react to TTK Healthcare Q4 results?

Ans. TTK Healthcare shares are trading at Rs 922.6 as of May 30, 2026. The stock movement post-results reflects market assessment of the quarterly earnings against Healthcare / Pharma sector expectations.

Should investors buy TTK Healthcare shares based on TTK Healthcare Q4 results?

Ans. Investment decisions should factor in the full Q4 FY26 financials for TTK Healthcare, FY27 growth outlook, current valuation, and personal risk profile. Always consult a SEBI-registered investment adviser before investing.

What risks should investors watch after TTK Healthcare Q4 results?

Ans. Key risks for TTK Healthcare include Healthcare / Pharma sector headwinds, macroeconomic uncertainty, input cost volatility, and working capital pressure. Investors should track quarterly updates and management commentary to assess the risk-reward profile for the stock in FY27.